Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (NBIX) is a leading neuroscience-focused biopharmaceutical company developing innovative therapies for complex neurological, endocrine, and neuropsychiatric disorders. This comprehensive news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives driving the company's mission to address unmet medical needs.
Stay informed with verified updates spanning FDA decisions, clinical trial results, research collaborations, and market expansion efforts. Our curated news collection covers essential developments including movement disorder therapies like Ingrezza® for tardive dyskinesia, endocrine disorder treatments, and emerging pipeline candidates in neuropsychiatry.
Key focus areas include updates on late-stage clinical programs, partnership announcements with academic institutions, and analyses of therapeutic innovations targeting conditions from Huntington's disease chorea to congenital adrenal hyperplasia. All content is rigorously sourced to ensure accuracy and relevance for both professional investors and medical stakeholders.
Bookmark this page for centralized access to Neurocrine Biosciences' latest scientific advancements, financial disclosures, and treatment development progress. Check regularly for objective reporting on one of biopharma's most innovative neuroscience-focused enterprises.
Neurocrine Biosciences, Inc. (NBIX) will present at the BofA Securities 2024 Health Care Conference, featuring top executives discussing the company's commitment to developing life-changing treatments for neurological disorders. The conference will be webcasted live and a replay will be available on the company's website. Neurocrine Biosciences has a strong portfolio of FDA-approved treatments and a robust pipeline in late-stage development.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present key information at the European Congress of Endocrinology 2024, including baseline characteristics data from CAHtalyst™ Program of crinecerfont in CAH, and data from modified-release hydrocortisone studies in primary adrenal insufficiency and CAH. The presentations will cover pediatric and adult baseline characteristics data in congenital adrenal hyperplasia, Phase 2 Clinical Study Data for Modified-Release Hydrocortisone, Phase 3 Extension Study Data for Modified-Release Hydrocortisone in CAH, and more.
Neurocrine Biosciences, Inc. (NBIX) supports Tardive Dyskinesia Awareness Week to advocate for routine screening and monitoring of TD, a movement disorder caused by antipsychotic medication affecting approximately 600,000 people in the U.S. annually.
Neurocrine Biosciences presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024, highlighting the need for novel treatments in children and adolescents with Congenital Adrenal Hyperplasia (CAH). The data showcased the challenges in long-term CAH management, emphasizing the limitations of current treatment approaches and the difficulties in disease management as patients age into adulthood. Additionally, positive top-line data from previous Phase 3 clinical studies supported two New Drug Applications submitted to the FDA in April 2024.
Neurocrine Biosciences reported first-quarter 2024 financial results, with INGREZZA net product sales of $506 million, representing 23% growth year-over-year. They also announced FDA approval for INGREZZA SPRINKLE capsules and submitted New Drug Applications for crinecerfont. Positive Phase 2 data for NBI-1065845 in major depressive disorder was highlighted, along with strong financial performance and a robust pipeline, positioning the company as a neuroscience leader.
Neurocrine Biosciences, Inc. announced the U.S. FDA approval of INGREZZA SPRINKLE (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. This new oral granules formulation provides an alternative administration option for patients with swallowing difficulties. INGREZZA SPRINKLE offers three effective dosages and can be easily sprinkled on soft food for oral administration.
